Acquisition Opportunity IMARC was acquired by Avania in June 2021, signaling a potential shift in strategic focus and integration with a larger CRO network. This presents a sales opportunity to align with Avania’s extended services, potentially offering complementary trials, device-focused expertise, or expanded global support to existing and new clients.

Device CRO Focus Position IMARC as a niche partner for medical device trials within a bigger CRO ecosystem. Their background as a medical device CRO and Ohio headquarters can be leveraged to target device manufacturers seeking compliant, cost-effective monitoring, auditing, and training across FDA and global approvals.

Quality Assurance Highlight ongoing or upcoming QA capabilities and leadership changes as a pathway to upsell quality management services, audits, and training. The appointment of a dedicated Quality Assurance Manager historically signals emphasis on compliance and process improvements valuable to sponsors seeking robust site oversight.

Scale and Access With a lean team size of 51-200 and revenue in the low-to-mid single digits, there is a market need for scalable solutions, training programs, and technology-enabled monitoring. Propose value-add platforms or services that improve efficiency, reduce site chaos, and support rapid onboarding for multicenter studies.

Technology Enablement IMARC’s tech stack includes cloud hosting, analytics, CMS, and integration with professional networks. This suggests readiness for digital collaboration, data analytics, and content-driven training partnerships. Offer targeted tech-enabled trial management tools or HubSpot-based marketing and training programs to deepen sponsor relationships.